

Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy

Information for the public

Published: 6 September 2023

www.nice.org.uk

Mavacamten (Camzyos) is available on the NHS as a possible treatment for symptomatic obstructive hypertrophic cardiomyopathy in adults who have a New York Heart Association class of 2 to 3.

You can only have it alongside standard care that includes (unless they're unsuitable):

- beta-blockers
- non-dihydropyridine calcium-channel blockers or
- disopyramide.

If you are not eligible for mavacamten but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on cardiomyopathy](#) may be a good place to find out more.

[Cardiomyopathy UK](#) (0800 018 1024) can give you advice and support.

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5302-8